Heart Rhythm Society and Milestone Pharmaceuticals Enhance SVT Education for Patients with New Resources

Enhancing SVT Patient Education: A Collaboration Between Heart Rhythm Society and Milestone Pharmaceuticals

On June 1, 2026, the Heart Rhythm Society (HRS) announced a significant partnership with Milestone Pharmaceuticals aimed at elevating patient education on supraventricular tachycardia (SVT). This initiative coincides with SVT Awareness Day, which occurs on June 3 each year, a day dedicated to raising awareness about this common yet often misunderstood heart rhythm disorder.

SVT is an abnormal heart rhythm characterized by episodes of unexpectedly rapid heartbeats, impacting an estimated two million individuals across the United States. While many cases can be effectively managed, untreated SVT can lead to dire complications, including deteriorated quality of life and even heart failure. The partnership aims to establish a robust support system for patients and caregivers that aids in understanding SVT, its symptoms, treatment options, and effective communication with healthcare providers.

The cornerstone of this educational initiative is the new resources available through UpBeat.org, the educational platform managed by HRS. Noteworthy additions include a downloadable SVT Patient Info Sheet, and two videos: one explaining what SVT is along with its causes and symptoms, and another reviewing various treatment approaches. Additionally, a new interview titled "Understanding SVT: What Patients and EPs Want Each Other to Know" aims to bridge the gap in communication between patients and electrophysiologists (EPs).

Dr. Sana M. Al-Khatib, President of the Heart Rhythm Society, emphasized the importance of this partnership, noting that